WO2010013129A1 - Combinación coccidicida para uso veterinario - Google Patents
Combinación coccidicida para uso veterinario Download PDFInfo
- Publication number
- WO2010013129A1 WO2010013129A1 PCT/IB2009/006409 IB2009006409W WO2010013129A1 WO 2010013129 A1 WO2010013129 A1 WO 2010013129A1 IB 2009006409 W IB2009006409 W IB 2009006409W WO 2010013129 A1 WO2010013129 A1 WO 2010013129A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- toltrazuril
- coccidicidal
- combination
- trimethoprim
- veterinary composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract description 56
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229960000898 toltrazuril Drugs 0.000 claims abstract description 43
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 32
- 241000271566 Aves Species 0.000 claims description 32
- 208000003495 Coccidiosis Diseases 0.000 claims description 22
- 241000287828 Gallus gallus Species 0.000 claims description 22
- 206010023076 Isosporiasis Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 235000013330 chicken meat Nutrition 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- 244000144977 poultry Species 0.000 claims description 9
- 235000013594 poultry meat Nutrition 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 241000272517 Anseriformes Species 0.000 claims description 4
- 241000286209 Phasianidae Species 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 235000020354 squash Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 239000008233 hard water Substances 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 241000223932 Eimeria tenella Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 210000003046 sporozoite Anatomy 0.000 description 8
- 241000224483 Coccidia Species 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003250 oocyst Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 241000223924 Eimeria Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 206010061217 Infestation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000001165 anti-coccidial effect Effects 0.000 description 3
- WQGJEAMPBSZCIF-WHSSCRKSSA-N azanium;2-[(2r,3s,4s,5r,6s)-6-[(1r)-1-[(2r,5r,7s,8r,9s)-2-[(2s,5r)-5-[(2r,3s,5r)-3-[(2r,4s,5s,6s)-4,5-dimethoxy-6-methyloxan-2-yl]oxy-5-[(2s,3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]oxolan-2-yl]-5-methyloxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxasp Chemical compound [NH4+].O1[C@@H](C)[C@H](OC)[C@@H](OC)C[C@H]1O[C@@H]1[C@H]([C@]2(C)O[C@@H](CC2)[C@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](OC)[C@H](C)[C@@](O)(CC([O-])=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 WQGJEAMPBSZCIF-WHSSCRKSSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- -1 etopabate Chemical compound 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- MOOFYEJFXBSZGE-QJUDHZBZSA-N 1,2-bis[(z)-(4-chlorophenyl)methylideneamino]guanidine Chemical compound C=1C=C(Cl)C=CC=1\C=N/N=C(/N)N\N=C/C1=CC=C(Cl)C=C1 MOOFYEJFXBSZGE-QJUDHZBZSA-N 0.000 description 1
- FKBYRZCVXYSLEL-UHFFFAOYSA-N 1h-triazine-4,5,6-trione Chemical class O=C1NN=NC(=O)C1=O FKBYRZCVXYSLEL-UHFFFAOYSA-N 0.000 description 1
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZDPIZLCVJAAHHR-UHFFFAOYSA-N Clopidol Chemical compound CC1=NC(C)=C(Cl)C(O)=C1Cl ZDPIZLCVJAAHHR-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 241000304695 Eimeria sp. Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012571 GlutaMAX medium Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930182504 Lasalocid Natural products 0.000 description 1
- 108010007843 NADH oxidase Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- UKHWDRMMMYWSFL-UHFFFAOYSA-N Nicarbazin Chemical compound CC=1C=C(C)NC(=O)N=1.C1=CC([N+](=O)[O-])=CC=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 UKHWDRMMMYWSFL-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003683 amprolium Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960000731 clopidol Drugs 0.000 description 1
- 239000003224 coccidiostatic agent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960000248 diclazuril Drugs 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- PJBQYZZKGNOKNJ-UHFFFAOYSA-M hydron;5-[(2-methylpyridin-1-ium-1-yl)methyl]-2-propylpyrimidin-4-amine;dichloride Chemical compound Cl.[Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C PJBQYZZKGNOKNJ-UHFFFAOYSA-M 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
- 229960000320 lasalocid Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000253 proventriculus Anatomy 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 229960004591 robenidine Drugs 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 108010011792 succinate oxidase Proteins 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Definitions
- the present invention is related to the techniques used in obtaining and preparing compositions, medicaments and drugs for veterinary and zootechnical use, and more particularly, it is related to a coccidicidal combination based on the compound 1-methyl-3- [3-methyl -4- [4- (trifluoromethyl) thio) phenoxyl] phenyl] -1, 3,5-triazine (1 H, 3H, 5H) -2,4,6-trione better known as toltrazuril; and, of compound 5-
- trimethoprim [(3,4,5-Trimethoxyphenyl) methyl] pyrimidin-2,4-diamine known as trimethoprim, both compounds in combination show a synergistic effect that accelerates the recovery of birds and other animals affected by coccidiosis.
- the combination of the present invention has improved stability when applied in the drinking water for use.
- This disease in birds is caused by protozoa of the genus Eimer ⁇ a sp, of which 9 species have been identified, 4 of them having the highest incidence in poultry in Mexico, mainly in chickens, these four species are Eimer ⁇ a acervulina, Eimera maximum, Eimera necatr ⁇ x and Eimera tenella, which year after year cause significant damage to the poultry industry.
- Coccidiosis is transmitted by direct or indirect contact with the feces of infected birds.
- the disease begins when a bird ingests the protozoan in question also called coccidia, which invades the intestinal mucosa of the bird causing tissue damage as it reproduces.
- the protozoan produces descendants called oocysts, which, when expelled with the excrement, cannot infest another bird unless they go through a maturation process (sporulation), which occurs in a period of one to three days, after sporulation, the protozoan is infective if it is consumed by another bird.
- sporulation maturation process
- the severity of the infestation depends on the pathogenicity of the strain and the number of infectious coccidia consumed by the bird, for example, the infestation can be mild enough to go unnoticed, while a very large amount of coccidia can cause severe injuries that result in death.
- the Coccidia are easily transmitted from one chicken coop to another through contaminated footwear or clothing, free birds, equipment, food bags, insects and rodents.
- Coccidiosis usually occurs in growing chickens and in young adults, although it can also occur in other stages.
- the signs of an outbreak of coccidiosis are expressed in pale and weak birds, which tend to snuggle up, consume less food and water, birds with diarrhea and with signs of dehydration. In laying birds with coccidiosis, they experience a decrease in posture.
- the lesions produced by the infestation depend on the kind of coccidia causing the problem, its severity and the stage in which the disease is.
- Cecal coccidiosis can cause swelling of the cecal bags, which are filled with fresh blood.
- the blind man is filled with a material of caseous appearance and stained with varying amounts of blood.
- the lesions of intestinal coccidiosis vary from a fairly mild enteritis to a necrotic or hemorrhagic type.
- anticoccidians are products of chemical or biological nature. According to their mode of application, chemical anticoccidians are broadly classified into coccidiostats that are normally added or mixed with the food of birds and coccidicides that are normally added to the water that birds drink.
- nicarbazine sulfonamides (sulfa)
- diclazuril etopabate
- clopidol clopidol
- decocinate robenidine
- 3- nitro-4 acid -hydroxy-feliarsonic as well as ionophores compounds such as Maduramycin, Salinomycin, Lasalocid and Mone.nsin.
- toltrazuril is undoubtedly one of the compounds mostly used for the treatment of coccidiosis in birds, in this sense US Patents 4,631, 218; 5,141, 938 and 5,256,631; as well as European patent EP 1 246 624 mention anticoccidial products that include toltrazuril.
- toltrazuril for avian use can be acquired, for example, under the Baycox® 2.5% brand of the Bayer company.
- This formulation based on toltrazuril, has shown an acceptable performance, however, it is always desirable to have more effective compositions and where the birds that suffer from the disease have a faster recovery and with the least sequelae, that is, the poultry farmer always You want more effective formulations.
- toltrazuril-based formulations has shown application problems, particularly it is observed that the compositions easily precipitate in the water where they are solubilized to be available for which they do not become completely assimilated by the birds.
- toltrazuril the traditional way of applying toltrazuril is to empty it and dilute it in the containers that supply water to the drinking fountains of the ; birds, however, the drinking fountains are formed with small diameter pipes and filters that can be clogged by toltrazuril when it precipitates, in this way, the birds do not receive the appropriate doses of medication.
- toltrazuril in order to preserve the effectiveness of the commercial form of toltrazuril, it needs to be mixed with water with a low salt content, which is a condition that, in reality, is difficult to comply with in Mexico and other countries.
- coccidicidal compositions are required that have an enhanced effectiveness for faster recovery and with the lowest sequelae of infected animals, and coccidicidal compositions that do not lose effectiveness when mixed with any type of water.
- the best weight ratio between the components of the combination of the present invention is in the range of 1: 1 to 1: 5 (trimethoprim / toltrazuril).
- a coccidicidal veterinary composition comprising toltrazuril, trimethoprim and a pharmaceutically acceptable carrier, the composition may be formulated for oral administration.
- a solution or a suspension that forms a solution when mixed with water another method of application is the direct form in the oral cavity of each animal.
- Another aspect of the invention is the use of a therapeutically effective amount of a combination formed by toltrazuril and trimethoprim for the preparation of a medicament useful in the treatment of coccidiosis in birds and mammals.
- a method of treatment against coccidiosis for mammals and birds is provided using a therapeutically effective amount of the combination formed by toltrazuril and trimethoprim.
- Figure 1 is a graph showing the results obtained in comparative tests in vitro using a modality of the combination of the present invention and prior art compositions for the treatment of coccidiosis, the tests being done in chicken fibroblasts.
- trimethoprim a combination of the compound 1-methyl- 3- [3-methyl-4- [4- (trifluoromethyl) thio) phenoxy] phenyl] -1,3,5-tria2ine (1 H, 3H, 5H) -2,4,6-trione, referred to hereafter as toltrazuril; and, of the compound 5 - [(3,4,5-trimethoxyphenyl) methyl] pyrimidin-2,4-diamine, hereinafter referred to as trimethoprim, has a synergistic effect in the treatment of coccidiosis, particularly helping birds to recover faster from the disease and with the least number of sequelae than what was obtained with each of the products separately.
- trimethoprim it is preferred to use a weight ratio of trimethoprim with respect to toltrazuril of 1: 1 to 1: 5 (trimethoprim / toltrazuril).
- toltrazuril is a derivative of triazinetrione
- its use has been widely known in chickens, turkeys, calves and pigs for the prevention and treatment of coccidiosis when administered in water to drink from animals or directly in oral cavity.
- Toltrazuril has the following chemical structure (I).
- the second compound of the combination of the present invention and that is trimethoprim has the following chemical structure (II):
- Trimethoprim is a bacteriostatic antibacterial mainly used in the prophylaxis of urinary tract infections. During the development of the present invention, it was found that the best weight ratio between said components is from 1: 1 to 1: 5 (trimethoprim / toltrazuril), below that interval the combination ceases to have the required therapeutic effect and for Above there are problems with precipitation of the formulation, especially trimethoprim.
- a veterinary combination is formulated, using as pharmaceutically acceptable organic or inorganic liquids or solids, among which are starch, lactose, glucose, sucrose, dextrin, cellulose, paraffin, water, alcohol, polyethylene glycol, propylene glycol, triethanolamine, gum arabic, carbopol, poloxamers, chitosan, alpha beta and cyclodestrins range, dimethyl sulfoxide, etc.
- organic or inorganic liquids or solids among which are starch, lactose, glucose, sucrose, dextrin, cellulose, paraffin, water, alcohol, polyethylene glycol, propylene glycol, triethanolamine, gum arabic, carbopol, poloxamers, chitosan, alpha beta and cyclodestrins range, dimethyl sulfoxide, etc.
- the veterinary composition of the present invention is formulated for oral administration, more preferably, it is preferred to formulate a composition for oral administration, in the form of a suspension or solution. Moreover, it is preferred to prepare a suspension for oral administration comprising 20 to 30 mg of toltrazuril for each ml of suspension; and, from 20 to 150 mg of trimethoprim per ml of suspension. Below the minimum values indicated for each component, the composition simply does not have the required effectiveness, while at higher values, especially trimethoprim, the composition precipitates.
- the suspension or solution can be mixed with water from a ratio greater than or equal to 1: 1000 (solution / water), and has a basic pH, preferably, from 8.5 to 12.5.
- the veterinary composition formulated for oral administration can be applied to birds with age from 1 day onwards, for those birds with ages from 10 to 18 days, the composition can be administered for 1 or 2 consecutive days. Recommended values are 5 to 10 mg / kg body weight for two consecutive days.
- the combination with synergistic effects between toltrazuril and trimethoprim is used for the preparation of a veterinary medicament useful in the treatment of coccidiosis in birds and mammals, more particularly, its application in poultry selected from group comprising chickens, turkeys, ducks and geese, being preferably applied in chickens.
- chicken fibroblasts of the rhoO line, CS-3 cell line [Gurnett et al., 1995 AM Gurnett, PM Dulski, SJ. Darkin-Rattray, MJ.
- the fibroblasts were maintained at 41 0 C in the presence of 5% CO 2 in Ham's F-12-Glutamax medium, supplemented with 10% heat-inactivated fetal bovine serum, 100 Ul / ml penicillin, 100 ⁇ g / ml streptomycin, 50 ⁇ g / ml uridine and 1 mM sodium pyruvate.
- Eimerias - Non-sporulated oocyst cultures of Eimeria tenella, strain PAPt37, obtained in turn from the Department of Parasitology of the Faculty of Veterinary Medicine and Zootechnics of the National Autonomous University of Mexico. Sporozoites were obtained by exorption of sporulated oocysts according to that described by Dulski and Turner, 1988 P. Dulski and M. Turner, The purif cation of sporocysts and sporozoites from Eimeria tenella oocysts using Percoll density gradients, Avian Diseases 32 (1988), pp. 235-239.
- Example 1 Maduramycin (10 ⁇ g / ml) (as a witness to the efficacy of the test)
- Example 4 Maduramycin + toltrazuril (5 ⁇ g / ml + 5 ⁇ g / ml)
- Example 5 Toltrazuril + diminacene diaceturate (5 ⁇ g / ml + 10 ⁇ g / ml)
- Example 6 Toltrazuril + pyrimethamine (5 ⁇ g / ml + 2 ⁇ g / ml)
- Baycox® 2.5% (Bayer of Mexico)
- a dose of 1 ml / L of a suspension prepared according to Table 2 and a dose of the commercial product were used Baycox®, on the 5th and 6th day post-inoculation in chickens infected experimentally with E. tenella.
- the chickens were raised in 40 cm wire cages. tall, 50 cm. wide and 1 m. long, from 1 to 28 days. When the different test groups were formed from 21 to 28 days, the same equipment was used.
- a fresh inoculum was used based on a field strain of E. tenella, from which the dose of 100,000 oocysts sporulated per bird was administered.
- the already titled sporulated inoculum was provided at the tip of each bird by a graduated syringe by depositing it in the proventriculus with a rigid probe at 28 days of age.
- toltrazuril such as trimethoprim are capable of stimulating the death of schizont in coccidia by inhibition of the respiratory chain, in particular at the level of cytochrome-C reductase and Ia NADH oxidase, as well as via the succinate oxidase.
- veterinary compositions were prepared according to the percentages listed in Table 8, the purpose of said two compositions was to analyze the behavior of the composition in hard water by varying the concentration of trimethoprim.
- Each veterinary composition was prepared in the following manner, in a container with polyethylene glycol, a predetermined amount of trimethoprim was added gradually to achieve the concentration indicated in Table 8 and mixed for 10 minutes. Subsequently, triethanolamine was added and mixed for another 5 minutes, then, an amount of toltrazuril sufficient to achieve the concentration indicated in Table 8 was added and allowed to mix for an additional 5 minutes. Then, ethanol was added and the vessel was covered, the mixture was heated to 4O 0 C with stirring for an additional 30 minutes. At the end of this operation, a cloudy-off-white suspension was obtained.
- Each of the veterinary compositions of examples 8 and 9 was diluted in water with varying degrees of hardness, as indicated in Table 9, where qualitatively the solubility and precipitation of the compositions of examples 8 and 9 were determined.
- composition prepared according to example 9 (2.5% Trimethoprim) had a better solubilization in the 3 types of water, in comparison with the composition of example 8.
- compositions When preparing the compositions, they have a basic or alkaline pH so that no problem is contemplated when dosed in hard water, since both the composition and the water have alkaline pH, for this reason, there will be no problems of ionization or the active principles, neither of the components of the formulation and therefore would not affect the water dosing system pipe.
- the component of the composition that tends to settle is trimethoprim. EXAMPLE 10.
- Solubility varying the dose and varying the concentration of water hardness.
- a suspension according to the present invention was prepared containing 2.5% toltrazuril with 0.5% trimethoprim, resulting in a pH of 10.7, which was compared against the commercial drug Baycox® (Bayer of Mexico) containing 2.5% toltrazuril with a pH of 9.3. Both were tested in different doses before water with different hardness concentration measured in parts per million (ppm) of calcium carbonate in order to verify the solubility or precipitation of both compounds once they are used in livestock facilities. The results obtained are shown in Table 10. Table 10
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK09802583.6T DK2319515T3 (da) | 2008-07-31 | 2009-07-30 | Coccidicid kombination til veterinær anvendelse |
BRPI0911719A BRPI0911719A8 (pt) | 2008-07-31 | 2009-07-30 | composição coccidiocida e seu uso |
PL09802583T PL2319515T3 (pl) | 2008-07-31 | 2009-07-30 | Kombinacja przeciwko kokcydiom do zastosowania weterynaryjnego |
ES09802583.6T ES2475266T3 (es) | 2008-07-31 | 2009-07-30 | Combinación coccidicida para uso veterinario |
EP09802583.6A EP2319515B1 (en) | 2008-07-31 | 2009-07-30 | Coccidicide combination for veterinary use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2008/009818 | 2008-07-31 | ||
MX2008009818A MX2008009818A (es) | 2008-07-31 | 2008-07-31 | Combinacion coccidicida para uso veterinario. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010013129A1 true WO2010013129A1 (es) | 2010-02-04 |
Family
ID=41610000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/006409 WO2010013129A1 (es) | 2008-07-31 | 2009-07-30 | Combinación coccidicida para uso veterinario |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2319515B1 (es) |
AR (1) | AR072889A1 (es) |
BR (1) | BRPI0911719A8 (es) |
CL (1) | CL2011000208A1 (es) |
CO (1) | CO6341549A2 (es) |
DK (1) | DK2319515T3 (es) |
DO (1) | DOP2011000030A (es) |
ES (1) | ES2475266T3 (es) |
MX (1) | MX2008009818A (es) |
PE (1) | PE20110401A1 (es) |
PL (1) | PL2319515T3 (es) |
PT (1) | PT2319515E (es) |
WO (1) | WO2010013129A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2610346A1 (en) | 2011-12-28 | 2013-07-03 | BETA RENEWABLES S.p.A. | Improved pre-soaking process for biomass conversion |
WO2016181187A1 (es) * | 2015-05-11 | 2016-11-17 | Laboratorio Avi-Mex, S.A. De C.V. | Composición para el tratamiento de parasitosis por gregarinas en camarones |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552477A (zh) * | 2010-12-09 | 2012-07-11 | 天津瑞贝特科技发展有限公司 | 治疗鸡球虫病的中药组合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631218A (en) | 1983-11-16 | 1986-12-23 | Stig Olofsson | Wooden base plate |
US5141938A (en) | 1990-05-17 | 1992-08-25 | Bayer Aktiengesellschaft | Parasiticidal substituted 1,2,4-triazinediones |
US5256631A (en) | 1991-06-19 | 1993-10-26 | Bayer Aktiengesellschaft | Substituted 1,2,4-triazinediones, and their use |
WO1998043644A1 (en) * | 1997-03-31 | 1998-10-08 | David Granstrom | Formulations and methods to treat and prevent equine protozoal myeloencephalitis |
EP1246624A2 (de) | 1999-12-03 | 2002-10-09 | Bayer Aktiengesellschaft | Triazinonverbindungen zur behandlung von durch den befall mit parasitischen protozoen bedingten krankheiten |
-
2008
- 2008-07-31 MX MX2008009818A patent/MX2008009818A/es active IP Right Grant
-
2009
- 2009-07-30 EP EP09802583.6A patent/EP2319515B1/en not_active Not-in-force
- 2009-07-30 DK DK09802583.6T patent/DK2319515T3/da active
- 2009-07-30 ES ES09802583.6T patent/ES2475266T3/es active Active
- 2009-07-30 AR ARP090102918A patent/AR072889A1/es unknown
- 2009-07-30 PT PT98025836T patent/PT2319515E/pt unknown
- 2009-07-30 BR BRPI0911719A patent/BRPI0911719A8/pt not_active Application Discontinuation
- 2009-07-30 PL PL09802583T patent/PL2319515T3/pl unknown
- 2009-07-30 WO PCT/IB2009/006409 patent/WO2010013129A1/es active Application Filing
- 2009-07-30 PE PE2011000097A patent/PE20110401A1/es not_active Application Discontinuation
-
2011
- 2011-01-28 DO DO2011000030A patent/DOP2011000030A/es unknown
- 2011-01-31 CL CL2011000208A patent/CL2011000208A1/es unknown
- 2011-02-28 CO CO11023780A patent/CO6341549A2/es not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631218A (en) | 1983-11-16 | 1986-12-23 | Stig Olofsson | Wooden base plate |
US5141938A (en) | 1990-05-17 | 1992-08-25 | Bayer Aktiengesellschaft | Parasiticidal substituted 1,2,4-triazinediones |
US5256631A (en) | 1991-06-19 | 1993-10-26 | Bayer Aktiengesellschaft | Substituted 1,2,4-triazinediones, and their use |
WO1998043644A1 (en) * | 1997-03-31 | 1998-10-08 | David Granstrom | Formulations and methods to treat and prevent equine protozoal myeloencephalitis |
EP1246624A2 (de) | 1999-12-03 | 2002-10-09 | Bayer Aktiengesellschaft | Triazinonverbindungen zur behandlung von durch den befall mit parasitischen protozoen bedingten krankheiten |
Non-Patent Citations (7)
Title |
---|
A.M. GUMETT; P.M. DULSKI; S.J. DARKIN-RATTRAY; M.J. CARRINGTON; D.M. SCHMARTZ: "Selective labeling of intracellular parasite proteins by using ricin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 92, 1995, pages 2388 - 2392J |
HARDER A: "Haberkom A possible mode of action of toltrazuril: studies on two Eimeria species and mammalian and Ascaris suum enzymes", PARASITOL RES, vol. 76, no. 1, 1989, pages 8 - 12 |
HARDER, A. ET AL.: "Possible mode of action of toltrazuril: studies on two Eimeria species and mammalian and Ascaris suum enzymes", PARASITOL. RES., vol. 76, 1989, pages 8 - 12, XP008142774 * |
M.H. BINGER; D. HUG; G. WEBER; E. SCHILDKNECHT; M. HUMBELIN; L. PASAMONTES: "Cloning characterization of a surface antigen of Eimeria Tenella merozoites and expression using a recombinant vaccinia virus", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 61, 1993, pages 179 - 187 |
P. DULSKI; M. TUMER: "The Purification of sporocysts and sporozoites from Eimeria Tenella oocysts using Percoli density gradients", AVIAN DISEASES, vol. 32, 1988, pages 235 - 239 |
See also references of EP2319515A4 * |
VOYVODA, H. ET AL.: "Clinical Hepatozoon canis infection in a dog in Turkey", JOURNAL OF SMALL ANIMAL PRACTICE, vol. 45, no. 12, 2004, pages 613 - 617, XP008142757 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2610346A1 (en) | 2011-12-28 | 2013-07-03 | BETA RENEWABLES S.p.A. | Improved pre-soaking process for biomass conversion |
WO2013098789A1 (en) | 2011-12-28 | 2013-07-04 | Beta Renewables S.P.A. | Improved pre-soaking process for biomass conversion |
US20130168602A1 (en) * | 2011-12-28 | 2013-07-04 | Beta Renewables, S.p.A. | Pre-soaking process for biomass conversion |
US9102856B2 (en) * | 2011-12-28 | 2015-08-11 | Beta Renewables, S.p.A. | Pre-soaking process for biomass conversion |
WO2016181187A1 (es) * | 2015-05-11 | 2016-11-17 | Laboratorio Avi-Mex, S.A. De C.V. | Composición para el tratamiento de parasitosis por gregarinas en camarones |
Also Published As
Publication number | Publication date |
---|---|
CL2011000208A1 (es) | 2011-05-06 |
PT2319515E (pt) | 2014-05-27 |
PL2319515T3 (pl) | 2014-10-31 |
EP2319515A1 (en) | 2011-05-11 |
AR072889A1 (es) | 2010-09-29 |
EP2319515A4 (en) | 2011-12-21 |
MX2008009818A (es) | 2010-02-01 |
DK2319515T3 (da) | 2014-06-30 |
PE20110401A1 (es) | 2011-07-24 |
CO6341549A2 (es) | 2011-11-21 |
BRPI0911719A2 (pt) | 2015-10-06 |
ES2475266T3 (es) | 2014-07-10 |
DOP2011000030A (es) | 2011-04-15 |
BRPI0911719A8 (pt) | 2018-03-06 |
EP2319515B1 (en) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Burka et al. | Drugs in salmonid aquaculture–a review | |
JP2007520515A (ja) | 家禽におけるコクシジウム症の処置のためのシマルバアマラ及び/又はモモルディカカランティア抽出物 | |
TWI429397B (zh) | 含有葉酸合成抑制劑及/或葉酸活性化抑制劑之組成物的用途 | |
US5063219A (en) | Anticoccidial composition | |
WO2010013129A1 (es) | Combinación coccidicida para uso veterinario | |
CN105832759B (zh) | 一种预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病的药物组合物 | |
US20160250244A1 (en) | Compositions for treating heartworm infestation | |
D’Agostino | Insectivores (insectivora, macroscelidea, scandentia) | |
US20080249153A1 (en) | Anthelmintic formulations | |
JPH0840935A (ja) | 家禽類のコクシジウム症に対して免疫を付与する方法 | |
ES2372915T3 (es) | Neomicina para el aumento de la sobrevivencia de animales acuáticos expuestos a ipnv. | |
CN103536603B (zh) | 一种可湿性磺胺间甲氧嘧啶(钠)粉剂及其制备方法 | |
Wernery et al. | Viral diseases | |
JP4629964B2 (ja) | ウシの消化器疾患治療剤 | |
EA001623B1 (ru) | Соединения из класса ацилмочевин, предназначенные для лечения кокцидиоидомикоза у теплокровных животных | |
WO2006095433A1 (ja) | ウシの消化器疾患治療剤 | |
ES2928418T3 (es) | Uso de vidofludimus para el tratamiento de infecciones por coronavirus | |
ES2913405T3 (es) | Composiciones veterinarias para alimento de liberación retardada con actividad ovicida y larvicida contra cepas susceptibles y resistentes de parásitos en heces de rumiantes, uso de estas composiciones, método para retardar la liberación de estas composiciones | |
CN102000100A (zh) | 一种抗球虫的纳米混悬剂及其配制方法 | |
RU2067865C1 (ru) | Способ лечения и профилактики инвазионных заболеваний | |
Simon et al. | THE MANAGEMENT AND CONTROL OF Coccidiosis eimeria SPECIES IN GUINEA FOWL (Numidia meleagritis galeata pallas) UNDER INTENSIVE REARING SYSTEM | |
BR112017024363B1 (pt) | Composições alimentícia compreendendo toltrazuril e trimetoprima e uso de uma combinação de toltrazuril e trimetoprima para o tratamento de parasitose por gregarinas em camarões | |
NZ758435B2 (en) | Delayed release feed-through veterinary compositions with ovicidal and larvicidal activity against susceptible and resistant strains of parasites in ruminants' feces, use of these compositions, method for delaying the release of these compositions | |
Shrestha et al. | Section VII—Nepal | |
Shoemaker et al. | Overviewand Infectious of Fish Diseases Immune System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09802583 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 000097-2011 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011000208 Country of ref document: CL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011020196 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009802583 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11023780 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: PI0911719 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110131 |